Barclays lowered the firm’s price target on Zimmer Biomet to $125 from $130 and keeps an Underweight rating on the shares. The analyst says the company’s new guidance is by “no means a lay-up.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet initiated with a Neutral at Goldman Sachs
- Zimmer Biomet formalizes partnership with CBRE
- Zimmer Biomet board approves new stock buyback authorization for up to $2B
- Zimmer Biomet targets mid-single-digit revenue CAGR in 2024-2027
- JMP Securities healthcare analysts hold an analyst/industry conference call